# Latest Breakthroughs in Alzheimer’s Treatments Unveiled! Newsy: Alzheimer’s News Weekly Published: 2026-10-26T13:30:02.221Z Source: https://newsyai.com/edition/a1a2d2de-2512-4691-86cb-ff1d52b4f0c8 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- **Alzheimer’s Treatment Briefing: Fresh Data on Approved Therapies, Tau-Targeting Advances, and Early-Stage Candidates** **Coverage period: October 19–26, 2026** Broad searches across news outlets, research databases, regulatory announcements, and trial registries for the past seven days highlight new long-term data on an approved treatment, updated trial results for a tau-focused therapy, and promising signals from other candidates. These build on ongoing efforts without overlapping prior editions’ focus areas. Here are the key stories worth highlighting, ranked by potential near-term relevance to care. **1. Donanemab (Kisunla) shows lasting amyloid reduction after treatment ends** **Overview** New long-term extension data from the TRAILBLAZER-ALZ 2 Phase 3 trial, presented at the AD/PD 2026 conference, indicate that patients who completed donanemab treatment and cleared most amyloid plaques maintained those low levels for up to three years. Amyloid reaccumulated slowly afterward, at a rate similar to natural buildup in older adults. Many participants needed no further dosing once plaques were sufficiently reduced.[[1]](https://www.psychiatrictimes.com/view/developments-in-donanemab-with-brandy-matthews-md) **Why this matters** Imagine amyloid plaques as unwanted buildup clogging a vital system; clearing them thoroughly appears to keep the “pipes” clear longer than expected, without constant medication. This could mean simpler, shorter treatment courses for eligible patients, reducing burden while preserving benefits—offering practical guidance for using this already-approved option. **2. Diranersen Phase 2 results show clinical slowing signals and strong tau reductions; Phase 3 planned** **Overview** Biogen’s Phase 2 CELIA trial of diranersen (an antisense oligonucleotide targeting tau) in early Alzheimer’s did not meet its primary endpoint for a clear dose-response on one cognitive measure. However, pre-specified analyses across doses showed slowing of cognitive and functional decline, strongest at the lowest dose tested. All doses produced substantial, sustained reductions in tau protein levels in spinal fluid and on brain scans. The company plans to advance to Phase 3.[[2]](https://www.neurologylive.com/view/topline-phase-2-celia-results-show-diranersen-misses-primary-end-point-early-ad) **Why this matters** Tau tangles are like tangled wiring that disrupts brain cell communication and leads to decline. This therapy directly targets tau production and shows meaningful downstream effects on both the protein and thinking skills in early disease. Positive signals despite a missed primary endpoint keep tau-targeting approaches in play as a potential complement to amyloid-focused treatments. **3. Valiltramiprosate biomarker data links biological changes to clinical benefits in early Alzheimer’s** **Overview** Analyses from prior Phase 2 and Phase 3 studies of oral valiltramiprosate (an amyloid-oligomer inhibitor) showed consistent reductions in the key blood marker p-tau217, especially in people with mild cognitive impairment. These biomarker shifts correlated with better scores on thinking tests and protection of brain volume in key areas. A new Phase 3 study is planned.[[3]](https://www.neurologylive.com/view/biomarker-data-across-studies-support-disease-targeted-effects-valiltramiprosate) **Why this matters** This oral candidate appears to influence core disease processes in a measurable way that tracks with real-world thinking and brain health outcomes. If confirmed in larger trials, an easy-to-take pill option could expand access and allow earlier or combination use alongside infusions. **4. UCLA candidate drug boosts protective protein and improves memory in Alzheimer’s mouse models** **Overview** Researchers identified DDL-357, a small molecule that increases levels of secreted clusterin (a protective brain protein). In Alzheimer’s mouse models, it lowered toxic phospho-tau, supported mitochondrial function (the cell’s energy factories), and improved performance on memory tests. The approach is still in early preclinical testing but could complement existing therapies.[[4]](https://www.uclahealth.org/news/release/candidate-drug-boosts-protective-brain-protein-mice-has) **Why this matters** Think of clusterin as a natural cleanup crew that helps manage harmful proteins and supports cell energy. Boosting it internally may address multiple trouble spots at once. Early results suggest a path toward treatments that not only slow damage but also help restore function—though human trials are years away. **What this means for care right now** - Approved treatments like donanemab (Kisunla) and lecanemab (Leqembi) remain options for eligible early-stage patients; discuss long-term data, monitoring, and personalized plans with your doctor. - Lifestyle factors (heart health, exercise, sleep, social engagement) continue to support brain health. - Clinical trial participation remains important for accessing emerging approaches—online tools can help match patients. - New trial results and biomarker insights are refining how therapies work and who may benefit most; genetic insights and blood tests are making risk assessment and monitoring more practical. - Research continues to explore multi-target and convenient options beyond single approaches. **Sources** - Psychiatric Times coverage of donanemab long-term extension data from TRAILBLAZER-ALZ 2 (presented October 2026).[[1]](https://www.psychiatrictimes.com/view/developments-in-donanemab-with-brandy-matthews-md) - NeurologyLive reports on diranersen CELIA Phase 2 topline and full data (October 2026).[[2]](https://www.neurologylive.com/view/topline-phase-2-celia-results-show-diranersen-misses-primary-end-point-early-ad) - NeurologyLive biomarker analyses for valiltramiprosate from Phase 2/3 studies (October 2026).[[3]](https://www.neurologylive.com/view/biomarker-data-across-studies-support-disease-targeted-effects-valiltramiprosate) - UCLA Health release on DDL-357 candidate drug (October 23, 2026).[[4]](https://www.uclahealth.org/news/release/candidate-drug-boosts-protective-brain-protein-mice-has) - Comprehensive web searches for Alzheimer’s news, trials, and announcements covering October 19–26, 2026 (conducted October 26, 2026). Research continues to deliver layered insights that could refine and expand future care options.